# Insulin Resistance and Androgen Deprivation Therapy

> **NCT04995978** · PHASE2 · WITHDRAWN · sponsor: **St. Louis University**

## Conditions studied

- Prostate Cancer
- Insulin Resistance

## Interventions

- **DRUG:** Pioglitazone 30 mg
- **DRUG:** placebo tablet

## Key facts

- **NCT ID:** NCT04995978
- **Lead sponsor:** St. Louis University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-01-18
- **Final completion:** 2023-01-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants were recruited and the study was deemed not feasible
- **Last updated:** 2023-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04995978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04995978, "Insulin Resistance and Androgen Deprivation Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04995978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*